Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.


Cook Medical initiates clinical study to evaluate post-treatment removal of the Evolution® Oesophageal Fully Covered Stent

Cook Medical has initiated a clinical study in the U.S. to evaluate the removability of a new Evolution® Oesophageal Fully Covered Stent. This is the first multicenter U.S. study to evaluate the possibility of removing a self-expanding metal stent after malignant and benign strictures have been treated. The stent design used in the study has been modified to accommodate retrieval. The study will also evaluate the use of the device in oesophageal conditions, including strictures, fistulae, perforations or leaks.

The study, led by Principal Investigator Dr John Vargo MD, MPH and chairman of Gastroenterology and Hepatology at the Cleveland Clinic, is a prospective, single-arm study. Patients can be enrolled in the study when they require a stent for an obstruction that is caused by an intrinsic or extrinsic malignancy or a refractory benign oesophageal stricture. Also, patients that have an oesophageal fistula, perforation or leak can be included in the study. There are additional eligibility criteria for the study.

“Defining the role of removable stents in benign and malignant oesophageal disorders is still a quandary for clinicians,” said Dr Vargo, “This multicenter study which involves many of the leading centers in therapeutic endoscopy, should help answer this question.”

The Evolution Oesophageal study will be conducted at up to 15 sites across the U.S. and will enroll 130 patients. Patients will be followed for the duration of stent placement up to six months.  After endoscopic stent removal, specified patients will have a 30-day follow-up that will complete his or her enrollment.

“We are very excited to see where this study takes us,” said Barry Slowey, global leader of Cook Medical’s Endoscopy division. “We hope that the results of this study will allow for some expanded treatment options for malignant and benign oesophageal diseases.”

Caution- Investigational device. Limited by Federal (or United States) law to investigational use.

Dr Vargo is a paid consultant for Cook Medical.

Thank You for Your Interest in Cook Medical's Products

The product information on this website is intended only for physicians and healthcare professionals licensed in the European Union (except France), the United Kingdom, Switzerland, Norway, Iceland, Turkey, and Liechtenstein. If you are located in another global region, please click on the regional flag at the very top of the webpage and choose your region from the drop-down options.

If your region is not listed, visit our How to Order section for more information.

Information provided on this site is not intended to be professional medical advice. Product Instructions for Use (IFU) should be consulted before use of any product.